Metabolic control of primed human pluripotent stem cell fate and function by the miR-200c–SIRT2 axis

Young Cha, Min-Joon Han, Hyuk-Jin Cha, Janet Zoldan, Alison Burkart, Jin Hyuk Jung, Yongwoo Jang, Chun-Hyung Kim, Ho-Chang Jeong, Byung-Gyu Kim, Robert Langer, C. Ronald Kahn, Leonard Guarente and Kwang-So Kim

A hallmark of cancer cells is the metabolic switch from oxidative phosphorylation (OXPHOS) to glycolysis, a phenomenon referred to as the ‘Warburg effect’, which is also observed in primed human pluripotent stem cells (hPSCs). Here, we report that downregulation of SIRT2 and upregulation of SIRT1 is a molecular signature of primed hPSCs and that SIRT2 critically regulates metabolic reprogramming during induced pluripotency by targeting glycolytic enzymes including aldolase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, and enolase. Remarkably, knockdown of SIRT2 in human fibroblasts resulted in significantly decreased OXPHOS and increased glycolysis. In addition, we found that miR-200c-5p specifically targets SIRT2, downregulating its expression. Furthermore, SIRT2 overexpression in hPSCs significantly affected energy metabolism, altering stem cell functions such as pluripotent differentiation properties. Taken together, our results identify the miR-200c–SIRT2 axis as a key regulator of metabolic reprogramming (Warburg-like effect), via regulation of glycolytic enzymes, during human induced pluripotency and pluripotent stem cell function.

In the early twentieth century, Otto Warburg observed a metabolic switch in transformed cells compared to normal cells from OXPHOS to glycolysis, even in the presence of high levels of oxygen. Interestingly, recent studies showed that the metabolism of different types of stem cells, in particular primed pluripotent stem cells (for example, human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs)), is also biased towards glycolysis rather than OXPHOS, exhibiting a Warburg-like effect. Indeed, more recent studies showed that this metabolic switch from OXPHOS to glycolysis is critical for bioenergetics, biosynthetic capacity, and epigenetic regulation in hPSCs, which was further supported by metabolomics analyses. Unlike hESCs and hiPSCs that represent a primed state, mouse ESCs are known to be at a naïve state and energetically bivalent, and can dynamically switch from glycolysis to OXPHOS on demand. Thus, these studies suggest that metabolic reprogramming is intimately linked to stem cell identity during induced pluripotency. However, at present, the molecular mechanism underlying metabolic reprogramming is poorly understood.

Recent proteomics studies revealed that numerous proteins of the nucleus, cytoplasm, and mitochondria involved in diverse aspects of cellular metabolism are highly acetylated in human, mouse, and prokaryotic cells. In particular, virtually all enzymes involved in glycolysis and the tricarboxylic acid cycle were found to be acetylated in human liver tissues, strongly suggesting that protein acetylation is a key mechanism regulating metabolism, which prompted us to hypothesize that protein acetylation regulates, at least in part, metabolic reprogramming. Protein acetylation can be modulated by histone acetyl transferase (HATs), as well as by class I, II, III, and IV histone deacetylases (HDAC). Among these, class III HDACs, termed sirtuins, are NAD-dependent protein deacetylases that are highly conserved from bacteria to humans. In particular, sirtuins are the only HDACs whose activity is dependent on NAD, a critical cofactor of cell metabolism, we further hypothesized that certain sirtuin members play important roles in regulating metabolic reprogramming.

Here, we report that altered acetylation levels of glycolytic enzymes by SIRT2 downregulation critically regulate metabolic control of primed human pluripotent stem cell fate and function by the miR-200c–SIRT2 axis.

Received 11 March 2017; accepted 20 March 2017; published online 24 April 2017; DOI: 10.1038/ncb3517
reprogramming during human induced pluripotency and influence stem cell function and regulation in primed hPSCs.

RESULTS

Warburg-like effect in hPSCs

To compare energy metabolism between hPSCs and their somatic counterpart, we compared hPSCs from human dermal fibroblasts (hDFs) by introducing four reprogramming genes (c-Myc, Oct4, Sox2, and Klf4) and confirmed pluripotency markers gene expression, almost identical morphology, and pluripotent differentiation potential in the resulting hiPSCs and in hESCs (Supplementary Fig. 1a–c). In addition, intracellular ATP levels as well as oxygen consumption rate (OCR) were significantly lower in hESCs and hiPSCs compared to hDFs (Supplementary Fig. 1d,e). Since the Warburg effect is closely related to increased glucose uptake by upregulation of glucose transporters (GLUTs) in cancer cells,16, we compared the expression levels of GLUT genes. As shown in Supplementary Fig. 1f, GLUT1-4 mRNAs were significantly upregulated in both iPSCs and hESCs compared to fibroblasts. Taken together, these results, in line with previous findings, demonstrate that a Warburg-like effect is operating in primed hPSCs.

Glycolytic enzymes are highly acetylated in hPSCs

To address our hypothesis that acetylation affects the metabolic switch, we compared protein acetylation in hESCs and hDFs by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses following immunoprecipitation with acetyl-Lys antibody (Supplementary Fig. 1g). This proteomic analysis identified more than 200 acetylated proteins in both hDFs and hESCs. To minimize non-specificity, we excluded proteins with fewer than 10 peptide hits (black dots, Fig. 1a). The graph in Fig. 1a illustrates this proteomic analysis where proteins with higher acetylation (>1.5 fold) in hESCs (red dots) or in hDFs (blue dots) are shown. We found that a total of 28 and 15 proteins are hyper- and hypo-acetylated in hESCs compared to hDFs, respectively (Supplementary Tables 1 and 2). In agreement with these results, western blot analyses confirmed that hESCs and hiPSCs contain higher levels of acetylated α-tubulin, well-characterized SIRT2 substrate,31 than hDFs, whereas they express similar levels of total α-tubulin (Fig. 1a, inset). Notably, this analysis revealed that 5 out of 10 glycolytic enzymes are hyperacetylated in hESCs: aldolase (encoded by ALDOA), glyceraldehyde-3-phosphate dehydrogenase (encoded by GAPDH), phosphoglycerate kinase (encoded by PGK1), enolase (encoded by ENO1), and pyruvate kinases (encoded by PKM1 and 2) (highlighted in red; Supplementary Table 1). Collision-induced dissociation (CID) spectra of the acetylated peptides derived from these glycolytic proteins are shown in Supplementary Fig. 2.

Downregulation of SIRT2 and upregulation of SIRT1 is a molecular signature of primed hPSCs

We next investigated if any acetylation-modulating factor(s) such as HATs or HDACs show a unique expression pattern in hPSCs compared to their counterpart somatic tissues by means of web-based meta-analyses. We analysed five independent studies of hPSCs against various sets of differentiated cell types (GSE28633; ref. 24, GSE18265; ref. 25, GSE20013; ref. 26, GSE39144 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39144), and GSE9709; ref. 27) using GEO2R (https://www.ncbi.nlm.nih.gov/geo/geo2r). We first searched if the expression of any acetyl transferase is consistently altered in hPSCs, but failed to find any in all five meta-analysis studies (Supplementary Table 3). We next analysed all known deacetylases: 11 HDACs (belonging to HDAC I, II, and IV) and 7 SIRTs (belonging to HDAC III). Remarkably, we found that SIRT2 is uniquely and consistently downregulated in all five independent meta-analyses (Supplementary Fig. 3a and Supplementary Table 4). In addition, SIRT1 is upregulated in hPSCs in four meta-analyses. In agreement with this, using another web-based database analysis tool (http://www.nextbio.com), we found that SIRT2 is significantly downregulated whereas SIRT1 is significantly upregulated in hESCs lines compared to human somatic cells (Fig. 1b and Supplementary Table 5), while expression levels of other sirtuins (SIRT3-7) were variable (Supplementary Fig. 3b–f). These findings prompted us to hypothesize that altered acetylation of metabolic enzymes by SIRT1 and/or SIRT2 plays a critical role(s) in metabolic reprogramming.

To test this, we examined their gene expression during induced pluripotency and in vitro differentiation. As shown in Fig. 1c,d, SIRT1 and SIRT2 expression (both mRNA and protein level) were prominently up- and downregulated in hPSCs compared to hDFs, respectively, showing that induced pluripotency accompanies SIRT1 induction and SIRT2 suppression. In contrast, during spontaneous differentiation, SIRT2 was highly upregulated whereas SIRT1 was downregulated along with pluripotency markers Oct4 and Sox2 (Fig. 1c,e). In addition, SIRT2 was robustly upregulated during differentiation of hESCs into midbrain dopamine neurons (Fig. 1g,i), as evidenced by dramatic increases in expression of Tuj1, tyrosine hydroxylase (TH), and Lmx1b (Fig. 1f,g), which was accompanied by a robust decrease in the expression of SIRT1, Oct4 and Nanog (Fig. 1h,i). Our results are in agreement with previous studies showing downregulation of SIRT1 during hESC differentiation28,30 and upregulation of SIRT2 during mouse ESC differentiation31.

Functional effects and targets of SIRT2

Because glycolytic enzymes including aldolase, GAPDH, PGK1, enolase, and pyruvate kinases are highly acetylated and the deacetylase SIRT2 is robustly downregulated in hESCs, we hypothesized that SIRT2 downregulation is responsible for their hyperacetylation, directly contributing to the Warburg-like effect. To address this, we generated stable hESC lines in which expression of SIRT2 and EGFP can be induced by doxycycline (Dox) (Fig. 2a and Supplementary Fig. 4a). Under our hESC culture condition using the chemically defined culture medium (E8) containing TGF-β, Dox-induced SIRT2 overexpression (OE) did not change expression levels of pluripotent markers (for example, Oct4, Nanog, Esrrb, and Rex1) or the morphology of hESCs compared to control cells (Fig. 2a and Supplementary Fig. 4b,c). Interestingly, forced expression of SIRT2 in TGF-β-free hESC culture condition resulted in spontaneous differentiation (Supplementary Fig. 4c), which is in line with the Moussaieff et al. study showing that inhibition of glycolysis causes a rapid loss of pluripotency in TGF-β-free culture condition.

We next investigated the effect of altered SIRT2 expression on acetylation and enzymatic activities of these glycolytic proteins. Remarkably, forced expression of SIRT2 in hESCs prominently deacetylated all four enzymes tested (aldolase, PGK1, enolase, and
SIRT2 downregulation and SIRT1 upregulation is a molecular signature of human pluripotency. (a) Immunoprecipitation of hDF and hESCs proteins using antibodies against acetyl-Lys, following LC-MS/MS analyses to identify acetylated proteins. Red and blue dots represent hyperacetylated proteins in hESCs and in hDFs, respectively. (b) Mean value scatter plot of relative expression levels of SIRT1 and SIRT2 in hESC lines (n = 25) and normal somatic cell lines (n = 15) using results from a database search (http://www.nextbio.com). All cell line information is shown in Supplementary Table 5. (Mean ± s.e.m., two-tailed unpaired Student’s t-test.) (c) SIRT1 and SIRT2 expression from hDFs, iPSCs and hESCs was determined by qRT-PCR. (Mean ± s.e.m., n = 3 biologically independent experiments, ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.005, one-way ANOVA with Newman–Keuls post-test.) (d) Protein levels of SIRT1 and SIRT2. (e) Relative mRNA levels of SIRT1, SIRT2, Oct4 and SOX2 during in vitro differentiation of hESCs. (n = 2 biologically independent experiments.) (f) Immunofluorescence assays of pluripotency markers (Oct4 and Tra-1-60) and neuronal markers (TH and Tuj1) before and after in vitro DA differentiation, respectively. Hoechst was used to show nucleus. Scale bar, 100 µm. (g,h) Gene expression levels of DA neuronal markers (TH, Lmx1b, and Tuj1) (g) and pluripotency markers (h) are shown along with those of SIRT1 and SIRT2. (Mean ± s.e.m., n = 3 biologically independent experiments, ∗P < 0.05; ∗∗∗P < 0.005, two-tailed unpaired Student’s t-test.) (i) SIRT1 and SIRT2 protein levels during in vitro DA differentiation. Statistics source data are in Supplementary Table 9. Unprocessed original scans of blots a,d,i are shown in Supplementary Fig. 9.

GAPDH) (Fig. 2b,c), whereas expression levels of their total proteins (see Input; Fig. 2b,c) and mRNAs (Supplementary Fig. 4d) were unchanged. PKM1 and 2 could not be analysed here due to the lack of isofrom-specific antibodies. Furthermore, we found that deacetylation of glycolytic enzymes by SIRT2OE in hESCs caused a significant decrease of enzymatic activities for all three enzymes tested (aldolase,
Figure 2 SIRT2 regulates acetylation and enzymatic activity of glycolytic enzymes. (a) Left: representative pictures of inducible SIRT2-GFP H9 hESCs with or without doxycycline (Dox). Scale bar, 100 μm. Right: the efficiency of SIRT2 overexpression was confirmed by western blotting with SIRT2-specific antibody. (b–d) Total protein extracts from wild-type (mock) and inducible SIRT2-GFP hESCs (SIRT2OE) with or without Dox were immunoprecipitated with anti-Aldolase A, anti-PGK1, anti-Enolase or anti-GAPDH antibodies (b) or anti-acetyl-Lys (c). Acetylation levels of each enzyme were assessed by western blotting with an anti-acetyl-Lys antibody (f) or each specific antibody (b) or each specific antibody (c). Enzymatic activities in each extracts are shown in (d). Enzymatic activities in each extracts are shown in (g). (Mean ± s.d., n = 3 biologically independent experiments, ***P < 0.005, two-way ANOVA with Bonferroni post-test.) (e) Total protein extracts from mock and SIRT2OE hDFs were used as control of equal concentration for the IP. (f, g) Total protein extracts from mock and SIRT2 knockdown (KD) hDFs were immunoprecipitated by anti-Aldolase A, anti-PGK1, anti-Enolase or anti-GAPDH antibodies. Acetylation levels and enzyme activity of Aldolase A, PGK1, Enolase, GAPDH were determined by western blotting with anti-acetyl-Lys antibody (f) and enzymatic assays (g), respectively. Aldolase A, PGK1, Enolase, GAPDH, and β-actin western blotting of whole cell lysate (input) from WT and SIRT2KD hDFs were used as control of equal concentration for the IP and enzymatic activity assays. (Mean ± s.d. shown. n = 3 biologically independent experiments. *P < 0.05, two-way ANOVA with Bonferroni post-test.) Statistics source data are in Supplementary Table 9. Unprocessed original scans of blots a–c, e, f are shown in Supplementary Fig. 9.

We investigated the effect of SIRT2 knockdown (KD) on glycolytic enzymes in hDFs using specific shRNAs. We found that acetylation levels of aldolase, enolase, PGK1 and GAPDH were substantially increased (Fig. 2b–d). SIRT2 bound to aldolase and enolase (Fig. 2e), demonstrating a direct interaction between SIRT2 and these enzymes. Next, we investigated the effect of SIRT2 knockdown (KD) on glycolytic enzymes in hDFs using specific shRNAs. We found that acetylation levels of aldolase, enolase, PGK1 and GAPDH were substantially increased.
in SIRT2KD hDFs, although the expression levels of their total proteins were similar (Fig. 2f). Furthermore, their enzymatic activities were significantly increased, demonstrating a direct correlation between their acetylation levels and activities (Fig. 2g).

We next sought to identify specific lysine residues and their functional effects using aldolase (AldoA) as an example. We found that a total of 6 and 8 Lys residues are highly acetylated in mock- and SIRT2KD cells, respectively (Fig. 3a and Supplementary Table 6). Interestingly, K111 and K322 are hyperacetylated in SIRT2KD cells, but not in control cells (Supplementary Fig. 5a–d and Supplementary Table 6). Acetylated and non-acetylated forms of AldoA peptides were well separated and the acetylated form of AldoA was shown to have a 42 higher m/z value due to the acetyl groups. According to protein blast searching (http://blast.ncbi.nlm.nih.gov/Blast.cgi), the K111, but not the K322, residue belongs to the catalytic domain/inter-subunit interface (Fig. 3b). Thus, the K322 residue may represent an as-yet-unidentified domain. In addition, sequence alignment of AldoA interface (Fig. 3b) shows that K111 and K322 are highly conserved among diverse species (Fig. 3b). To further determine whether K111 and/or K322 are critical for regulating AldoA by SIRT2, we mutated each of them to glutamine (acylated mimetic) or arginine (deacylated mimetic) and examined their activity. We found that mutation of K322, but not K111 to Q robustly increased the catalytic activity compared to wild type in both hDFs and 293T cells (Fig. 3c and Supplementary Fig. 5e). Moreover, SIRT2KD prominently activated wild-type AldoA and K111R, but not K322R (Fig. 3d and Supplementary Fig. 5f), demonstrating that K322 deacetylation by SIRT2 significantly downregulates its activity. Notably, the AldoA structure model showed that K322 is exposed to the outside surface of AldoA, suggesting its availability to bind to SIRT2 (crystal structure model of human AldoA (Protein Data Bank code: 1ALD)) (Fig. 3e). Taken together, we propose that SIRT2 directly controls the acetylation levels and enzymatic activities of glycolytic enzymes and contributes to metabolic reprogramming.

SIRT2 expression levels influence metabolism, cell survival, and pluripotent differentiation functions of hPSCs

We next tested if altered SIRT2 levels directly influence glycolytic metabolism in hPSCs by measuring extracellular acidification rate...
death was rescued by pretreatment with N-acetyl-L-cysteine (NAC), a potent ROS scavenger (Fig. 4h), strongly suggesting that induced SIRT2 levels can cause ROS-dependent apoptotic cell death, leading to compromised proliferation/self-renewal capacity.

Next, we investigated the effect of SIRT2OE on metabolic reprogramming during the early stage of differentiation. We examined mRNA expression patterns for pluripotency and lineage-specific early markers, and measured production of extracellular lactate, a key metabolite of glycolysis. As shown in Fig. 5a–c, SIRT2 expression was prominently upregulated within two days of differentiation along with early-differentiation markers including Pax6, Brachyury (B-T), and Sox17. Furthermore, ECAR levels were decreased as early as three days, while lactate production was significantly reduced at day 4 during in vitro differentiation (Fig. 5d,e). Remarkably, we found that Dox-induced SIRT2OE in H9 hESCs and hiPSC-1 during in vitro differentiation resulted in a significant reduction of ECAR and extracellular lactate production compared to control cells (Fig. 5d,e and Supplementary Fig. 7a–e). To further determine whether SIRT2 expression levels affect the pluripotent differentiation potential of hESCs, we examined expression patterns for various lineage markers at day 0, 3, 6, 9 or 12 (D0-D12) during spontaneous in vitro differentiation. Strikingly, SIRT2OE hESCs with Dox differentiated more efficiently than WT and SIRT2OE without Dox to all three germ layer lineages, as evidenced by staining with antibodies against ectodermal, endodermal, and mesodermal markers (Fig. 5f). Furthermore, expression levels of diverse lineage marker genes of all three germ layers were markedly increased in all four SIRT2OE hPSC lines with Dox compared to WT and SIRT2OE without Dox at all time points tested (D3-D12) (Fig. 5g and Supplementary Fig. 7f). Taken together, our results suggest that SIRT2 levels directly influence energy metabolism and regulate survival and pluripotent differentiation potential of hPSCs.

Expression levels of SIRT2 regulate energy metabolism in hDFs and influence the reprogramming process

We next addressed if proper regulation of SIRT2 expression is critical for induced pluripotency via regulating metabolic reprogramming. To this end, we determined whether altered SIRT2 expression induces a metabolic switch in fibroblasts. Indeed, SIRT2KD in fibroblasts resulted in significant metabolic changes, including decreased OCR and increased ECAR compared to control cells (Fig. 6a,b). Furthermore, compared to control, SIRT2KD cells showed significantly decreased OXPHOS capacity, as evidenced by decreases in basal respiration, ATP turnover, maximum respiration, and oxidative reserve, as well as OCR decrease after FCCP treatment (Fig. 6c–e). We next treated hDFs with reprogramming factors together with SIRT2KD. Notably, reprogramming cells with SIRT2KD showed significantly reduced oxidative metabolism at both day 3 and day 8, compared to control reprogramming cells (Fig. 6f–k). We also examined the dynamics of metabolic change by altered SIRT2 expression during the reprogramming process. As shown in Fig. 7a, 6 days post-transfection of Y4, SIRT2 expression was prominently downregulated. Furthermore, decreased OCR and increased ECAR levels were also observed as early as 6 days post-transfection, while lactate production was significantly induced at day 9 post-transfection (Fig. 7b–d). Importantly, we found that reprogramming cells with SIRT2KD resulted in significantly enhanced changes in OCR and ECAR levels and induction of extracellular lactate production compared to control reprogramming cells (Fig. 7a–d).

We next tested whether altered SIRT2 expression influences iPSC generation from fibroblasts. Indeed, SIRT2OE in hDFs interfered with iPSC generation by approximately 80% while SIRT2KD significantly increased the efficiency (Fig. 7e,f), suggesting that downregulation of SIRT2 is critical for iPSC generation, via enhancing metabolic reprogramming. In addition, SIRT1KD prominently reduced iPSC generation whereas its overexpression significantly enhanced it (Supplementary Fig. 8e,f), which is in agreement with previous studies. However, SIRT1OE with or without reprogramming factors in hDFs did not influence oxidative metabolism at day 3 (Supplementary Fig. 8b–d). Notably, SIRT1OE appears to enhance metabolic switch at day 6 (Supplementary Fig. 8h), which is likely due to an indirect effect by enhancing the reprogramming process (Supplementary Fig. 8e,f). To further test whether enhanced reprogramming by SIRT2KD depends on elevated glycolysis, we next tested the effects of 2-deoxy-glucose (2DG), a general inhibitor of glycolysis, on metabolic changes and iPSC generation. Notably, treatment with 0.2 mM 2DG decreased the glycolytic flux in Y4+SIRT2KD to the level of Y4 only without 2DG (Fig. 7h), resulting in the generation of iPSC-like colonies to the level of Y4 only without 2DG (Fig. 7i). In addition, when fibroblasts were treated with 0.5 mM 2DG, metabolic changes and increased generation of iPSC-like colonies by SIRT2KD were abrogated (Fig. 7g–i). Notably, SIRT1OE appears to enhance metabolic switch at day 6 (Supplementary Fig. 8h), which is likely due to an indirect effect by enhancing the reprogramming process (Supplementary Fig. 8e,f). To further test whether enhanced reprogramming by SIRT2KD depends on elevated glycolysis, we next tested the effects of 2-deoxy-glucose (2DG), a general inhibitor of glycolysis, on metabolic changes and iPSC generation. Notably, treatment with 0.2 mM 2DG decreased the glycolytic flux in Y4+SIRT2KD to the level of Y4 only without 2DG (Fig. 7h), resulting in the generation of iPSC-like colonies to the level of Y4 only without 2DG (Fig. 7i). In addition, when fibroblasts were treated with 0.5 mM 2DG, metabolic changes and increased generation of iPSC-like colonies by SIRT2KD were abrogated (Fig. 7g–i). Notably, SIRT1OE appears to enhance metabolic switch at day 6 (Supplementary Fig. 8h), which is likely due to an indirect effect by enhancing the reprogramming process (Supplementary Fig. 8e,f). To further test whether enhanced reprogramming by SIRT2KD depends on elevated glycolysis, we next tested the effects of 2-deoxy-glucose (2DG), a general inhibitor of glycolysis, on metabolic changes and iPSC generation. Notably, treatment with 0.2 mM 2DG decreased the glycolytic flux in Y4+SIRT2KD to the level of Y4 only without 2DG (Fig. 7h), resulting in the generation of iPSC-like colonies to the level of Y4 only without 2DG (Fig. 7i). In addition, when fibroblasts were treated with 0.5 mM 2DG, metabolic changes and increased generation of iPSC-like colonies by SIRT2KD were abrogated (Fig. 7g–i). Notably, SIRT1OE appears to enhance metabolic switch at day 6 (Supplementary Fig. 8h), which is likely due to an indirect effect by enhancing the reprogramming process (Supplementary Fig. 8e,f). To further test whether enhanced reprogramming by SIRT2KD depends on elevated glycolysis, we next tested the effects of 2-deoxy-glucose (2DG), a general inhibitor of glycolysis, on metabolic changes and iPSC generation. Notably, treatment with 0.2 mM 2DG decreased the glycolytic flux in Y4+SIRT2KD to the level of Y4 only without 2DG (Fig. 7h), resulting in the generation of iPSC-like colonies to the level of Y4 only without 2DG (Fig. 7i). In addition, when fibroblasts were treated with 0.5 mM 2DG, metabolic changes and increased generation of iPSC-like colonies by SIRT2KD were abrogated (Fig. 7g–i). Notably, SIRT1OE appears to enhance metabolic switch at day 6 (Supplementary Fig. 8h), which is likely due to an indirect effect by enhancing the reprogramming process (Supplementary Fig. 8e,f). To further test whether enhanced reprogramming by SIRT2KD depends on elevated glycolysis, we next tested the effects of 2-deoxy-glucose (2DG), a general inhibitor of glycolysis, on metabolic changes and iPSC generation. Notably, treatment with 0.2 mM 2DG decreased the glycolytic flux in Y4+SIRT2KD to the level of Y4 only without 2DG (Fig. 7h), resulting in the generation of iPSC-like colonies to the level of Y4 only without 2DG (Fig. 7i). In addition, when fibroblasts were treated with 0.5 mM 2DG, metabolic changes and increased generation of iPSC-like colonies by SIRT2KD were abrogated (Fig. 7g–i). Notably, SIRT1OE appears to enhance metabolic switch at day 6 (Supplementary Fig. 8h), which is likely due to an indirect effect by enhancing the reprogramming process (Supplementary Fig. 8e,f). To further test whether enhanced reprogramming by SIRT2KD depends on elevated glycolysis, we next tested the effects of 2-deoxy-glucose (2DG), a general inhibitor of glycolysis, on metabolic changes and iPSC generation. Notably, treatment with 0.2 mM 2DG decreased the glycolytic flux in Y4+SIRT2KD to the level of Y4 only without 2DG (Fig. 7h), resulting in the generation of iPSC-like colonies to the level of Y4 only without 2DG (Fig. 7i). In addition, when fibroblasts were treated with 0.5 mM 2DG, metabolic changes and increased generation of iPSC-like colonies by SIRT2KD were abrogated (Fig. 7g–i). Notably, SIRT1OE appears to enhance metabolic switch at day 6 (Supplementary Fig. 8h), which is likely due to an indirect effect by enhancing the reprogramming process (Supplementary Fig. 8e,f).
SIRT2 influences metabolism and cell survival of hPSCs. (a) Glycolytic bioenergetics of wild-type (mock) and inducible SIRT2-GFP H9 hESCs (SIRT2OE) with or without Dox were assessed using the Seahorse XF analyser. Mean ± s.d. shown, n = 3 biologically independent experiments. (b) Basal glycolytic rate, glycolytic capacity and glycolytic reserve from mock and SIRT2OE H9 hESCs with or without Dox was analysed by determining cell numbers every two days under ESC culture condition. (Mean ± s.d., n = 3 biologically independent experiments, *P < 0.05, one-way ANOVA with Bonferroni post-test.) (c) Cell proliferation of mock and SIRT2OE H9 hESCs with or without Dox was analysed by determining cell numbers every two days under ESC culture condition. (Mean ± s.d., n = 3 biologically independent experiments, *P < 0.005, two-way ANOVA with Bonferroni post-test.) (d) GFP-positive (GFP+) WT and SIRT2 H9 hESCs with or without Dox were mixed at a ratio of 1:1 with GFP-negative (GFP-) hESCs, respectively. The GFP+/GFP− ratios were measured at each passage. (Mean ± s.d., n = 3 biologically independent experiments, ***P < 0.005, two-way ANOVA with Bonferroni post-test.) (e) Apoptotic population of mock and SIRT2OE H9 hESCs with or without Dox for three days under ESC culture conditions measured by Annexin V/7-AAD staining. (f) Quantification of Annexin V positive cells in mock and SIRT2OE hESC lines (H9 and H7) and two iPSC lines (iPSC-1 and iPSC-2) with or without Dox. 1: Mock w/o Dox, 2: Mock with Dox, 3: SIRT2OE w/o Dox, 4: SIRT2OE with Dox. (Mean ± s.d., n = 3 biologically independent experiments, ***P < 0.005, one-way ANOVA with Bonferroni post-test.) (g) Intracellular ROS levels of mock and SIRT2OE hPSCs (H9 and hiPSC-1) with or without Dox. 1: Mock w/o Dox, 2: Mock with Dox, 3: SIRT2OE w/o Dox, 4: SIRT2OE with Dox. (Mean ± s.d., n = 5 biologically independent experiments, ***P < 0.005, one-way ANOVA with Bonferroni post-test.) (h) Effect of antioxidant on cell death of hPSCs (H9 and hiPSC-1) by SIRT2OE with or without Dox. 1: Veh only, 2: NAC, 3: Dox+NAC, 4: Dox+NAC. (Mean ± s.d., n = 3 biologically independent experiments, ***P < 0.005, one-way ANOVA with Bonferroni post-test.) Statistics source data are in Supplementary Table 9.

Interestingly, we found that miR-200c, known to be induced by Oct4 (ref. 40), prominently downregulates SIRT2 expression at both the mRNA and protein levels (Fig. 8a,b). Because our prediction analysis showed that SIRT2 could be targeted by miR-200c-5p but not
Figure 5 SIRT2 influences metabolism during early in vitro differentiation of hESCs. (a,b) Inducible SIRT2OE H9 hESCs were induced to differentiate spontaneously by culturing in serum-free ITSFn medium for up to 4 days, and gene expression levels of pluripotency markers (Oct4, Nanog, and Rex1) (a) and early-differentiation markers (Pax6, Brachyury (B-T), and Sox17) (b) were determined by qRT-PCR. (Mean ± s.d., n=3 biologically independent experiments, *P < 0.05; **P < 0.01, one-way ANOVA with Bonferroni post-test.) (c) Expression level of SIRT2 in SIRT2OE H9 hESCs with or without Dox during early differentiation. (Mean ± s.d., n=3 biologically independent experiments, *P < 0.05, one-way ANOVA with Bonferroni post-test.) (d) Glycolytic bioenergetics of mock and SIRT2OE H9 hESCs with or without Dox were assessed using the Seahorse XF analyser. (Mean ± s.d., n=3 biologically independent experiments, *P < 0.05, one-way ANOVA with Bonferroni post-test.) (e) Extracellular lactate production of mock and SIRT2OE H9 hESCs with or without Dox. (Mean ± s.d., n=3 biologically independent experiments, *P < 0.05; **P < 0.01; ***P < 0.005, one-way ANOVA with Bonferroni post-test.) (f) SIRT2OE H9 hESCs were induced to differentiate spontaneously for 7 days, and differentiating cells were immunostained for the presence of lineage-specific markers for ectoderm (Otx2), endoderm (Sox17), and mesoderm (B-T). Scale bar, 100 µm. (g) Heatmaps depicting gene expression levels of markers representing ectoderm (Pax6, Map2, GFAP and AADC), endoderm (Foxa2, Sox17, AFP, CK8 and CK18), and mesoderm (Msx1 and B-T) in wild-type (Mock) and inducible SIRT2-GFP (SIRT2OE) H9 and H7 hESC lines with or without Dox differentiated for up to 12 days under differentiation condition. 1: Mock w/o Dox, 2: Mock with Dox, 3: SIRT2OE w/o Dox, 4: SIRT2OE with Dox. (n=2 biologically independent experiments.) Statistics source data are in Supplementary Table 9.

miR-200c-3p (Fig. 8c and Supplementary Table 7), we determined the effect of each precursor miRNA oligomer on SIRT2 expression. Indeed, pre-miR-200c-5p, but not pre-miR-200c-3p or scrambled oligomers (Scr), significantly decreased the expression level of SIRT2 mRNA or protein (Fig. 8d,e). We also found that pre-miR-200c-5p, but not pre-miR-200c-3p or scrambled sequences, significantly decreased
**Figure 6** SIRT2KD facilitates metabolic reprogramming in fibroblasts during the induced pluripotency. (a,b) Oxygen consumption rate (OCR) (a) and ECAR (b) of human fibroblasts (hDFs) infected with control (siNS) or SIRT2 siRNA (siSIRT2) at 3 days after transfection were assessed by XF analyser. (Mean ± s.d., n = 3 biologically independent experiments, *P < 0.05, two-tailed unpaired Student’s t-test.) (c) OXPHOS capacity of hDFs infected with siNS or siSIRT2 at 3 days after transfection. (Mean ± s.d., n = 3 biologically independent experiments.) (d,e) Basal respiration, ATP turnover, maximum respiration, oxidative reserve (d) or relative OCR changes after FCCP injection (e) from siNS and siSIRT2 are shown in (c). (Mean ± s.d., n = 3 biologically independent experiments, **P < 0.01; ***P < 0.005, two-tailed unpaired Student’s t-test.) (f,g) OCR were shown for hDFs infected with lentiviruses expressing four reprogramming factors (Y4) and/or SIRT2 knockdown (SIRT2KD) at 3 (f) or 8 (g) days after transfection. (Mean ± s.d., n = 3 biologically independent experiments, *P < 0.05; **P < 0.01; ***P < 0.005, one-way ANOVA with Bonferroni post-test.) (h,i) Basal respiration, ATP turnover, maximum respiration, and oxidative reserve from Y4 and/or SIRT2KD at 3 (h) or 8 (i) days after transfection are shown in (f,g). (Mean ± s.d., n = 3 biologically independent experiments, *P < 0.05; **P < 0.01; ***P < 0.005, one-way ANOVA with Bonferroni post-test.) (j,k) OCR/ECAR ratio (j) or relative OCR changes after FCCP injection (k) from Y4 and/or SIRT2KD are shown in (f,g). (Mean ± s.d., n = 3 biologically independent experiments, *P < 0.05; **P < 0.01; ***P < 0.005, one-way ANOVA with Bonferroni post-test.) Statistics source data are in Supplementary Table 9.

The luciferase reporter expression of both identified MREs (Fig. 8f), indicating that miR-200c-5p downregulates SIRT2 expression by targeting these two MREs. Taken together, our results support a model in which miR-200c-5p suppresses SIRT2 expression, leading to metabolic reprogramming during human induced pluripotency (Fig. 8g).

**DISCUSSION**

Here, we uncovered a molecular signature consisting of SIRT2 downregulation and SIRT1 upregulation in primed hPSCs during the reprogramming process, which is critical for induced pluripotency. We found that SIRT2KD in human fibroblasts significantly increases
hiPSC generation while SIRT2OE prominently inhibits it. Regulation of SIRT1 expression is also critical for induced pluripotency but in the opposite direction: SIRT1OE significantly increases hiPSC generation whereas SIRT1KD robustly interferes with it. In line with their opposite direction of expression, it appears that SIRT1 and SIRT2 regulate induced pluripotency through distinct mechanisms and targets. For instance, our results highlight that acetylation levels and activities of glycolytic enzymes (for example, aldolase, PGK1, enolase, and GAPDH) are robustly regulated by SIRT2, but not SIRT1. In agreement with our results, previous studies showed upregulation of SIRT1 in hiPSCs and SIRT1’s important roles for generation of mouse iPSCs. In addition, the study by Si et al. showed that SIRT2 is upregulated during in vitro differentiation of mouse ESCs and SIRT2KD promotes mesoderm and endoderm lineages while compromising ectoderm differentiation. In contrast, our results show that SIRT2 regulates more fundamental stem cell functions such as metabolism, cell survival/death, and pluripotent differentiation potential in hPSCs. The different functional role(s) of SIRT2 between these two studies possibly reflect species differences (mouse versus human). Another possibility is that SIRT2 has distinct functional role(s) for different stem cell state. Unlike primed hPSCs, mouse ESCs are at a naive pluripotent state and energetically bivalent. Thus, SIRT2 influences somatic nuclear reprogramming through metabolic changes. (a) Time course of expression level of SIRT2 mRNA in hDFs infected with Y4 and/or SIRT2KD. (Mean ± s.e.m., n = 4 biologically independent experiments, ***P < 0.001). (b–d) Two-way ANOVA with Bonferroni post-test.) (b, c) OCR (b) and ECAR (c) in hDFs infected with Y4 and/or SIRT2KD were assessed by XF analyser. (Mean ± s.e.m., n = 4 biologically independent experiments, ***P < 0.001). (d) Measurement of lactate production from hDFs infected with Y4 and/or SIRT2KD. (Mean ± s.e.m., n = 3 biologically independent experiments, ***P < 0.005). (e, f) Effects of SIRT2OE or KD on iPSC generation. Upper: The efficiency of overexpression (e) or knockdown (f) was confirmed by western blotting with anti-SIRT2 antibody. Lower: Representative pictures of AP-positive colonies at 14 days post-infection (dpi). (Mean ± s.e.m., n = 3 biologically independent experiments, *P < 0.01, two-way ANOVA with Bonferroni post-test.) (g, h) Effects of glycolytic inhibitor, 2-deoxyglucose (2DG) on iPSC generation by Y4 and/or SIRT2KD at 8 days post-transduction were assessed by OCR (g) and ECAR (h). (Mean ± s.e.m., n = 4 biologically independent experiments, *P < 0.01, **P < 0.005, two-way ANOVA with Bonferroni post-test.) (i) Effects of 2DG on iPSC generation by Y4 and/or SIRT2KD. Representative pictures of AP-positive colonies at 14 days post-transduction. (Mean ± s.e.m., n = 3 biologically independent experiments, *P < 0.005, two-way ANOVA with Bonferroni post-test.) Statistics source data are in Supplementary Table 9. Unprocessed original scans of blots e, f are shown in Supplementary Fig. 9.
SIRT2 critically inhibits the enzyme activity of aldolase A. K322 resides perhaps lysine-specific. To further validate our findings, we performed LC-MS/MS analyses of aldolase A. We identified K111 and K322 as the functional effect of acetylation appears to be enzyme- and residue dependent. For instance, a glycolytic enzyme, phosphoglycerate mutase, was reported to be stimulated through deacetylation by SIRT2 (ref. 43).

However, other studies showed that the same enzyme's activity is reported to be stimulated through deacetylation by SIRT2 (ref. 43). Its precise regulatory mechanism(s) await further investigation. Notably, SIRT2 is the only sirtuin known so far that acetylation is inhibitory to the activities of most enzymes.

The functional acetylation of GAPDH, in particular, was shown to be linked to metabolic reprogramming by regulating glycolytic enzymes which also reside in the cytoplasm. While SIRT2’s regulation of glycolysis appears to critically inhibit the enzyme activity of aldolase A. This suggests that SIRT2 regulates OXPHOS through PGC1α, a master regulator of mitochondrial biogenesis41, its precise regulatory mechanism(s) await further investigation. Notably, SIRT2 is the only sirtuin known so far that acetylation is inhibitory to the activities of most enzymes. Furthermore, increasing GapA acetylation in Salmonella by Pat acetylase treatment increased its glycolysis activity42.

Our finding that there is a direct correlation between acetylation levels and enzymatic activities is surprising because it was suggested that acetylation is inhibitory to the activities of most enzymes42. For instance, a glycolytic enzyme, phosphoglycerate mutase, was reported to be stimulated through deacetylation by SIRT2 (ref. 43). However, other studies showed that the same enzyme's activity is downregulated by SIRT1 or SIRT2 (refs 44,45). In addition, a recent study showed that GAPDH is activated by acetylation of its K254 residue46. Furthermore, increasing GapA acetylation in Salmonella by Pat acetylase treatment increased its glycolysis activity46. Thus, the functional effect of acetylation appears to be enzyme- and perhaps lysine-specific. To further validate our findings, we performed LC-MS/MS analyses of aldolase A. We identified K111 and K322 as specific SIRT2 target sites and found that deacetylation of K322 by SIRT2 critically inhibits the enzyme activity of aldolase A. K322 resides...
on an outside surface with unknown functional domain, and our functional data will provide useful insights into this important enzyme and its regulation in diseases such as cancer.

Finally, we found that SIRT2 is suppressed by miR-200c, a miRNA induced in pluripotent stem cells by Oct4 (ref. 40), via binding sites in the sirtuin gene coding sequence. This miRNA enhances metabolic reprogramming via SIRT2 suppression and this appears to be a critical step of induced pluripotency (Fig. 8g). Indeed, enforced SIRT2OE is highly inhibitory to iPSC reprogramming in human cells. It should be of interest to determine whether this regulation of metabolism by the miR-200c–SIRT2 axis is also important for other types of stem cells (for example, adult stem cells, naive pluripotent stem cells, and cancer stem cells). A defect in this pathway could lead to abnormal stem cell functions and compromised development in embryos or dysfunctional tissues in adults. Further, manipulation of the metabolic control of cell fate and function via the miR-200c–SIRT2 axis may aid translational approaches that use stem cells for regenerative medicine and cell replacement therapy.

METHODS

Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.

Note: Supplementary Information is available in the online version of the paper.

ACKNOWLEDGEMENTS

This work was supported by NIH grants (NS084869, NS070577, and GM101420) and the National Research Foundation of Korea (2011-0030043). The authors are grateful to members of the Kim laboratory for critical discussions.

AUTHOR CONTRIBUTIONS

Y.C. and M.-J.H.: concept and design, collection and/or assembly of data, data analysis and interpretation, and writing. L.G., H.-J.C. and K.-S.K.: concept and design, data analysis and interpretation, and writing. I.Z., A.B., J.H.J., Y.J. and H.-C.J.: concept and design, data analysis and interpretation, and writing. J.Z., A.B., J.H.J., Y.J. and H.-C.J.: collection and/or assembly of data. C.H.K., B.-G.K., R.I. and C.R.K.: data analysis and interpretation.

COMPETING FINANCIAL INTERESTS

K.-S.K. is co-founder of NurrON Pharmaceuticals and the remaining authors have no financial conflict to disclose.

Published online at http://dx.doi.org/10.1038/nctb3517

Reprints and permissions information is available online at www.nature.com/reprints

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

1. Warburg, O. The metabolism of tumors in the body. J. Gen. Physiol. 8, 519–530 (1927).
2. Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
3. Rafalski, V. A., Mancini, E. & Brunet, A. Energy metabolism and energy-sensing pathways in mammalian embryonic and adult stem cell fate. J. Cell Sci. 125, 5597–5608 (2012).
4. Ito, K. & Suda, T. Metabolic requirements for the maintenance of self-renewing stem cells. Nat. Rev. Mol. Cell Biol. 15, 243–256 (2014).
5. Burgess, R. J., Agathoclous, M. & Morrison, S. J. Metabolic regulation of stem cell function. J. Intern. Med. 276, 12–24 (2014).
6. Zhang, J. et al. Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell 11, 589–595 (2012).
7. Falus, C. D., Dzeja, P. P., Nelson, T. J. & Terzic, A. Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell 11, 596–606 (2012).
8. Zhang, J. et al. Metabolic regulation in pluripotent stem cells during their differentiated interplay. PLoS ONE 6, e20914 (2011).
9. Falus, C. D., Dzeja, P. P., Nelson, T. J. & Terzic, A. Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell 11, 596–606 (2012).
10. Zhang, J. et al. Metabolic regulation in pluripotent stem cells during their differentiated interplay. PLoS ONE 6, e20914 (2011).
METHODS

Cell culture. Human BJ dermal fibroblasts (hDF) and HEK293T cells were purchased from ATCC and grown in Dulbecco’s modified Minimal Essential Medium (DMEM) supplemented with 2 mM l-glutamine, 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin (all from Invitrogen). For iPSC induction, DMEM/F-12 medium supplemented with 2 mM l-glutamine, 1 mM β-mercaptoethanol, 1x non-essential amino acids (NEAA), 20% knockout serum replacement (KSR), 100 µM L-glutamine, 100 µg/ml streptomycin and 10 ng/ml basic fibroblast growth factor (bFGF; all from Invitrogen) was used as the reprogramming medium. Two hESC lines (H7 [WA-07] and H9 [WA-09]) and hiPSC lines were maintained in Essential 8 medium (Invitrogen) using Matrigel Matrix (Corning Life Sciences) and passaged using 0.5 mM EDTA (Invitrogen) for gentle dissociation. No cell lines used in this study were found in the database of commonly misidentified cell lines that is maintained by ICLAC and NCBI Biosample. All cell lines were authenticated by Interspecies Determination (Isoenzyme Analysis and STR analysis) by the providing company and were routinely tested for mycoplasma detection using a Venor GeM Mycoplasma Detection Kit (Sigma-Aldrich).

Plasmid construction and lentivirus production. Human SIRT1 and SIRT2 coding sequences were PCR-amplified from hESCs (H9) and hDFs, respectively, then cloned into the pGEM-T Easy vector (Promega). The 2A sequence of the Thesasaengirus (T2A)-linked EGFP was amplified from plasmid pxCLE-EGFP (#20782, Addgene) by RT-PCR and cloned into the pGEM-T Easy vector. The SIRT1 and SIRT2 fragments were then cut off from the corresponding vectors and inserted into the pGEM-T-T2A-EGFP to generate pGEM-T-SIRT1-T2A-EGFP and pGEM-T-SIRT2-T2A-EGFP, respectively. The identity of the SIRT1-T2A-EGFP and SIRT2-T2A-EGFP constructs was confirmed by sequencing. Subsequently, they were introduced into the EcoRI site of the FUW-tetO vector (Addgene). Human AldoA-Myc constructs, the AldoA fragment was PCR-amplified from H9 hESCs, and then cloned into the pDNA3.1-Myc/His vector (Invitrogen). For the psichek-2 constructs, the CDS fragments were cloned downstream of the Renilla luciferase open reading frame. AldoA point mutations were generated by site-directed mutagenesis using a QuickChange II XL Site-Directed Mutagenesis kit (Agilent Technologies).

FUW-tetO-based lentiviral vectors containing the other individual reprogramming factors for Oct4 (#20726), Sox2 (#20724), Klf4 (#20725) or c-Myc (#20723) were purchased from Addgene. The polystronic human STEMCCA lentivector was kindly provided by G. Mostoslavsky (Boston University). Genetic knockdown of SIRT1 or SIRT2 was carried out using lentiviral shRNA plasmids targeting human SIRT1 (RHS3979-201750186, RHS3979-201750188, RHS3979-201750189, and RHS3979-201750190) or human SIRT2 (RHS3979-201750191, RHS3979-201768981, RHS3979-201768982, RHS3979-201768983, RHS3979-201768984, and RHS3979-201768985) that were obtained from GE Healthcare Dharmacon. For lentivirus production, lentiviral vectors were co-transfected with packaging plasmids into 293T cells, maintained in DMEM supplemented with 10% FBS, using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Supernatants containing lentivirus were harvested after 48 h after transfection and filtered using 0.45 µm Millex-HV (Millipore) filters to remove cell debris.

Human iPSC induction. Human iPSCs were generated using lentiviral particles from inducible lentiviral vectors or STEMCCA vectors to introduce the OSKM factors (Oct4, Sox2, Klf4, and c-Myc) into fibroblasts86. ES-like colonies formed after 3 weeks of viral infection and the observed ES-like colonies were handpicked and transferred onto mouse feeder cells (MEFs)-plated or on Matrigel-coated tissue culture plates to generate iPSC lines. iPSC colonies were mechanically picked until iPSC lines were established. One of the established iPSC clone (termed hiPSC-1) was used for further analyses. Authentication of the hiPSC-1 cell line was performed on the basis of puropluripotent gene expression.

Live cell metabolic analysis. Oxygen consumption rate (OCR) and extracellular acidification rates (ECAR) were measured using the XF96 or XF24 analyser (Agilent Technologies) according to the manufacturer’s instructions. Briefly, cells were plated into wells of an XF cell culture microplate and incubated at 37°C in a CO2 incubator for 24 h and then an overnight attachment. The assay was started after cells were equilibrated for 1 h in XF assay medium supplemented with 10 mM glucose, 5 mM sodium pyruvate and 2 mM glutamine in a non-CO2 incubator. Mitochondrial activity between hDFs and hESCs and/or iPSCs was measured through sequential injections of 1 µM oligomycin, 0.3 µM FCCP and 1 µM rotenone/antimycin A to calculate basal respiration rates (baseline OCR—rotenone/antimycin A OCR), ATP dependent (basal respiration rate—oligomycin OCR), maximum respiration (FCCP OCR— rotenone/antimycin A OCR), and oxidative reserve (maximum respiration rate—basal respiration rate). Glycolytic processes were measured by serial injections of 10 mM glucose, 1 µM oligomycin, and 100 mM 2-deoxyglucose to calculate basal glycolytic rate, glycolytic capacity (in response to oligomycin), and glycolytic reserve (glycolytic capacity—basal rate). Each plotted value was normalized to total protein quantified using a Bradford protein assay (Bio-Rad).

Immunoprecipitation. For immunoprecipitation assays, hESCs and hDFs lysates were incubated with specific antibodies against acetyl-Lys (Cell Signaling Technology, catalogue No. 4414, 1:100), aldolase (Santa Cruz Technology, catalogue No. sc-12059, 1:100), enolase (Cell Signaling Technology, catalogue No. 3810, 1:50), PGK1 (Santa Cruz Technology, catalogue No. sc-130335, clone No. 14, 1:100) or GADPH (Santa Cruz Technology, catalogue No. sc-32233, clone No. 65C, 1:50) at 4°C overnight. After addition of protein A/G UltraLink resin, samples were incubated at 4°C for 2 h. Beads were washed three times with PBS and proteins were released from the beads by boiling in SDS-sample loading buffer and analysed by SDS–PAGE.

Liquid chromatography mass spectrometry (LC-MS/MS). For identification of acetylated proteins, hESCs or hDFs (control) were grown in 100 mm dishes up to 60–70% confluence. Cells were collected, washed with PBS and lysed (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 1% SDS, and protease inhibitor cocktail). Whole cell lysate from hESCs and hDFs were incubated for 10 min on ice followed by centrifugation at 14,000g for 15 min at 4°C. Supernatants were collected and pellets were discarded. Protein concentrations were determined using the BCA assay (Pierce) using bovine serum albumin (BSA) as standard. For immunoprecipitation assays, 500 µg of hESC and hDF lysates were incubated with anti-acetyl-Lys antibody (Cell Signaling Technology, catalogue No. 4414, 1:100) at 4°C for overnight. After addition of Protein A/G UltraLink resin, samples were incubated at 4°C for 2 h. Beads were washed three times with PBS and proteins were released from the beads by addition of SDS-sample loading buffer. The eluted proteins were analysed by SDS–PAGE and the gel stained with Coomassie Blue. For LC-MS/MS analyses, the gel was de-stained and bands cut and processed as described. Briefly, acetylated proteins bands were divided into 10 mm pieces and subjected to in-gel digestion with trypsin. The digested peptides were separated by online reversed-phase chromatography using a Thermo Scientific Eazi nano LC II UHPLC equipped with an autosampler using a reversed-phase peptide trap Easy Column (100 µm inner diameter, 2 cm length) and a reversed-phase analytical Easy Column (75 µm inner diameter, 10 cm length, 3 µm particle size), both from Thermofisher Scientific, followed by electrospray ionization using a 30 µm (i.d.) nanobore stainless steel online emitter (Thermo Scientific) and a voltage set at 2.6 V, at a flow rate of 300 nL min⁻¹. The chromatography system was coupled in line with an LTQ-Orbitrap mass spectrometer. Spectra were searched against the Human IPI v3.7 DB using the Sorcerer 2 IIDA Sequest-based search algorithm, and comparative analysis of proteins identified in this study was performed using Scaffold 4. LC-MS/MS analysis was performed at the Biopolymers & Proteomics Core Facility of the David H. Koch Institute at MIT and at the Medicinal Bioconvergence Research Center at Seoul National University. To compare protein acetylation between hESCs and hDFs, we quantified the acetylated proteins in both samples based on spectral counts. The spectral counts were first normalized to ensure that average spectral counts per protein were the same in the two data sets56. A G test was used to judge statistical significance of protein abundance differences57. Briefly, the G value of each protein was calculated as follows,

\[ G = 2 \left( S_1 \ln(S_1/S_0) + S_2 \ln(S_2/S_0) \right) \]

where \( S_1 \) and \( S_2 \) are the detected spectral counts of a given protein in any of two samples for comparison. Although the theoretical distribution of \( G \) value is complex, these values approximately fit to the \( x^2 \) distribution (1 degree of freedom), allowing the calculation of related \( P \) values58. For identification of acetylation sites on AldoA, we pulled down Myc-conjugated AldoA proteins from 293T cells infected with AldoA-Myc-overexpressing plasmid together with empty or SIRT2KD lentiviruses using immunoprecipitation assays. The pulldown was monitored across multiple groups of hPSCs to determine gene expression changes.
digested with chymotrypsin, and analysed using an LTQ-Orbitrap ion-trap mass spectrometer from Thermo Scientific (Taplin Mass Spectrometry Facility, Harvard University (https://taplin.med.harvard.edu/home)).

Western blot analysis. Samples (50 μg) were loaded onto a 12% SDS-PAGE and separated by electrophoresis followed by transfer onto a piece of Immobilon PVDF membrane (Bio-Rad). After transfer, the membrane was blocked at room temperature with Tris-buffered saline (TBS) containing 0.1% Tween-20 and 5% (w/v) skim milk for 3–5 h and then incubated overnight at 4 °C with primary antibody. The membrane was washed three times with TBS containing 0.05% Tween-20 (TBS-T) and then incubated for 2 h with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Santa Cruz Biotechnology, 1:1000) or goat anti-rabbit IgG (Invitrogen, 1:3000). After washing twice with TBS-T and once with TBS, bound antibodies were detected by chemiluminescence using the SuperSignal West Pico kit (Pierce). Antibodies against acetyl-lys (Catalogue No. N9411, 1:1000) and Enolase (Catalogue No. 3810, 1:1000) were purchased from Cell Signaling Technology, β-actin (Catalogue No. ab8227, 1:1000), α-tubulin (Catalogue No. ab4074, 1:1000), acetylated-α-tubulin (Catalogue No. ab24610, clone No. 6-11B-1, 1:1000), SIRT1 (Catalogue No. ab33441, clone No. E104, 1:1000), and SIRT2 (Catalogue No. ab51023, clone No. EP166Y, 1:1000) from Abcam, Aldolase A (Catalogue No. sc-12059, 1:1000), PGK1 (Catalogue No. sc-130355, clone No. 14, 1:1000), GAPDH (Catalogue No. sc-23233, clone No. 6C5, 1:1000) from Santa Cruz Biotechnology. We used HRP-conjugated VeriBlot for IP secondary antibody (Abcam, catalogue No. ab11366, 1:500) to facilitate detection of immunoprecipitated proteins without co-detecting the IgG heavy and light chains. The PVDF membrane was stripped by washing three times with TBS-T followed by incubation at 50 °C for 30 min with shaking in stripping buffer (62.5 mM Tris-HCl, pH 6.7, 100 mM β-mercaptoethanol, and 2% SDS). After incubation, the membrane was washed several times with TBS-T. Stripped membranes were blocked and probed with primary and secondary antibodies as previously described.

Immunofluorescence. For immunofluorescence assays, cells were immediately fixed (2% formaldehyde, 100 mM KCl, 200 mM sucrose, 1 mM EGTA, 1 mM MgCl2, 10 mM PIPES, pH 6.8) for 10 min. Cells were washed with PBS three times and incubated with blocking solution containing 3% BSA in PBS for 15 min. Cells were washed with PBS three times and incubated with primary antibodies in blocking solution at 4 °C overnight. Oct4 (Catalogue No. sc-5279, clone No. C-10, 1:500) and Nanog (Catalogue No. sc-33759, 1:500) antibodies were obtained from Santa Cruz Biotechnologies, SSEA4 (Catalogue No. MBA4304, clone No. MC-813-70, 1:500), TRA-1-60 (Catalogue No. MBA4360, clone No. TRA-1-60, 1:500) and Tyrosine hydroxylase (TH, catalogue No. AB1542, 1:1000) antibodies from EMD Millipore, Otx2 (Catalogue No. AF1979, 1:500), Sox17 (Catalogue No. AF1924, 1:500) and Brachyury (Catalogue No. AF2085, 1:500) antibodies from R&D Systems, class III β-tubulin (TuJ1, catalogue No. MMS-435P, clone No. TuJ1, 1:500) antibody from Covance. Cells were washed with PBS three times and incubated with goat anti-mouse Alexa 488, donkey anti-rabbit Alexa 568 or donkey anti-sheep Alexa 568 (Invitrogen, 1:300) in blocking solution. After washing with PBS, nuclei were stained with Hoechst33342 (Invitrogen). Each image was examined using a confocal laser-scanning microscope (Olympus America).

Quantitative reverse transcription polymerase chain reaction (qRT-PCR). Total RNA was extracted from cells by using the Direct-zol RNA purification Kit (Zymo Research) and cDNA was synthesized using the Thermoscript RT-PCR system (Invitrogen). For quantitative analyses, qRT-PCR (Bio-Rad) were performed using SsoAdvanced SYBR Green supermix (Bio-Rad) and pre-amplified hESC lactate production was measured using L-Lactate assay (Cayman, Chemical) according to the manufacturer's instructions. Statistics and reproducibility. Data were analysed using GraphPad Prism 5.0.1 software (GraphPad Software) and are presented as mean with s.e.m. or s.d. (as indicated in figure legends). Statistic tests were performed and P value thresholds were obtained using GraphPad 5.0.1. Multiple groups were tested using analysis of variance (ANOVA) and comparisons between two groups were performed using two-tailed unpaired Student’s t-test. Statistically significant differences are indicated as follows: *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.001. Representative figures are shown in Figs 1a–d, f1, 2a–c.e.f, 3a, 4a, 5f, 7a–c and 8b and Supplementary Figs 1a–g, 4c and 8f. Each experiment was repeated independently: 2 repeats (Figs 1e and 3g and Supplementary Fig. 7f), 3 repeats (Figs 1a,c,d–f, 2, 3a,c,d, 4a–f, 5, 6, 7a–d and 8a,b,d–f and Supplementary Figs 1a–d,g, 4, 5e,f, 6, 7a–e and 8b–h), 4 repeats (Figs 7a–c,g and Supplementary Fig. 1e), 5 repeats (Fig. 4g).

Data availability. Previously published data sets are available under accession numbers GSE28633, GSE18265, GSE20013, GSE39144, and GSE9709. LC-MS/MS results used in this study have been provided in Supplementary Tables 1 and 2. All raw mass spectrometry proteomics data reported in this study have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the data set identifier PXD006036. Source data for Figs 1c,e,g,h, 2d,g, 3a,d, 4a–d,f,h, 5a–e, 6a–k, 7a–i and 8a,d,f, and Supplementary Figures 1d–f, 4d,b, 5e,f, 6a–h, 7a–f and 8b–h have been provided in Supplementary Table 9. Unprocessed western blots, including two repeat experiments for each blot, have been provided for Figs 1a,1b, 2b,c,e,f, 3a and 8b,e, and Supplementary Fig. 1d in Supplementary Fig. 9. All other data supporting the findings of this study are available from the corresponding author upon request.

47. Somers, A. et al. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 28, 1728–1740 (2010).
48. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).
49. Kislinger, T. et al. Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell 125, 173–186 (2006).
50. Zhou, J. Y. et al. Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach. J. Proteome Res. 9, 5133–5141 (2010).
51. Kim, D. et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4, 472–476 (2009).
Supplementary Figure 1  Warburg-like effect in hESCs and hiPSCs compared to hDFs. (a) Human ESCs (H9) and hiPSCs cultured under feeder-free condition were stained with specific antibodies against pluripotency markers (e.g., Oct4, Nanog, SSEA4, and TRA1-60) along with Hoechst nuclear staining. Scale bar, 100 μm. (b) Representative pictures of hESCs and hiPSCs. Scale bar, 100 μm. (c) In vitro spontaneous differentiation of hESCs and hiPSCs by culturing in serum-free ITSFn medium for 7 days. Immunostaining images (first and second row panels) show lineage specific markers for ectoderm (Otx2), mesoderm (Brachyury, B-T), and endoderm (Sox17). Scale bar, 100 μm. (d) Intracellular ATP levels were significantly lower in hiPSCs and hESCs than in the original fibroblasts. (mean ± s.e.m., n=3 biologically independent experiments, ***, p<0.005, two-tailed unpaired Student’s t-test). (e) Mitochondrial bioenergetics of parental hDFs and hiPSCs as well as hESCs assessed by Seahorse XF analyzer. (mean ± s.d., n=4 biologically independent experiments). (f) Expression levels of glucose transporters (GLUTs) including GLUT1 to GLUT7 in hDFs and hiPSCs as well as hESCs. (mean ± s.e.m., n=3 biologically independent experiments, * p<0.05; ** p<0.01; *** p<0.005; **** p<0.001, one-way ANOVA with Bonferroni post-test). (g) Immunoprecipitation of hDF and hESCs proteins using antibodies against acetyl-Lys, followed by LC-MS/MS analyses to identify acetylated proteins. Statistics source data are in Supplementary Table 9. Unprocessed original scans of blots (d,g) are shown in Supplementary Fig. 9.
Supplementary Figure 2 CID spectra for the acetylated proteins shown in Supplementary Fig. 1g and Supplementary Table 1. Peptides for tubulin, Fructose-bisphosphate aldolase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase1, enolase, pyruvate kinase isozymes M1/M2 and ATP synthase were detected via combination of IP and LC-MS/MS analyses. IP was performed with anti-acetyl-Lys antibody.
Supplementary Figure 3 Meta-analysis of Sirtuin family expression in hESCs. (a) Representative data showing SIRT2 expression changes between different cells. SIRT2 downregulation was observed in hPSCs compared to differentiated cells and original fibroblasts. (b-f) Mean value scatter plot of expression levels of SIRT3 (b), SIRT4 (c), SIRT5 (d), SIRT6 (e), and SIRT7 (f) in hESC lines (n=25) and normal somatic cell lines (n=15) using results from a Database search (http://www.nextbio.com). All cell lines information is shown in Supplementary Table 5. (mean ± s.e.m., two-tailed unpaired Student’s t-test).
Supplementary Figure 4 Characterization of inducible SIRT2-GFP H9 hESCs. (a) Plasmid map of doxycycline (Dox) inducible SIRT2-EGFP overexpression vector. (b) Expression levels of pluripotency markers in wild-type hESCs, hDFs, and SIRT2-GFP hESCs with or without Dox. (mean ± s.d., n=3 biologically independent experiments, *** p<0.005, one-way ANOVA with Bonferroni post-test). (c) Effects of TGF-β on spontaneous differentiation of SIRT2-GFP hESCs. Cells were maintained in hESC culture conditions with or without TGF-β. TGF-β was added for 4 days and cells were immunostained for expression of the endodermal marker Sox17; Scale bar, 100 μm. (d) Expression levels of glycolytic enzymes in SIRT2-GFP hESCs with or without Dox analyzed by qRT-PCR. (mean ± s.d., n=3 biologically independent experiments, *** p<0.005, two-tailed unpaired Student’s t-test). Statistics source data are in Supplementary Table 9.
Supplementary Figure 5 Effects of altered SIRT2 expression on acetylation of AldoA. (a–d) Detection of AldoA K111 (a,b) and K322 (c,d) acetylation by mass spectrometry analysis. Symbol @ indicates the acetylation site. (e) Myc-tagged AldoA, AldoA^K111Q, and AldoA^K322Q were each expressed in 293T cells. AldoA proteins were purified by IP with Myc antibody, and specific activity for AldoA was determined. (mean ± s.d., n=3 biologically independent experiments, *** p<0.005, one-way ANOVA with Bonferroni post-test). (f) Myc-tagged AldoA, AldoA^K111R, and AldoA^K322R were each expressed in 293T cells co-expressing SIRT2 shRNA (SIRT2KD). AldoA proteins were purified by IP with Myc antibody and specific activity for AldoA was determined. (mean ± s.d., n=3 biologically independent experiments, *** p<0.005, one-way ANOVA with Bonferroni post-test). Statistics source data are in Supplementary Table 9.
Supplementary Figure 6 Metabolic and functional characterization of hPSC lines following SIRT2 overexpression. (a,c,e) Glycolytic bioenergetics of wild type (Mock) and inducible SIRT2-GFP cell lines from H7 hESCs (a) and two iPSC lines (c,e) with or without Dox were assessed by XF analyzer. (mean ± s.d., n=3 biologically independent experiments). (b,d,f) Basal glycolytic rate, glycolytic capacity and glycolytic reserve of mock and SIRT2OE from H7 hESCs (b) and two iPSC lines (d,f) with or without Dox are shown in (a,c,e), respectively. (mean ± s.d., n=3 biologically independent experiments, * p<0.05; ** p<0.01, one-way ANOVA with Bonferroni post-test). (g) OCRs for two hESC lines (H9 and H7) and the hiPSC-1 line with or without Dox are shown. 1: Mock w/o Dox, 2: Mock with Dox, 3: SIRT2OE w/o Dox, 4: SIRT2OE with Dox. (mean ± s.d., n=3 biologically independent experiments, * p<0.05; *** p<0.005, one-way ANOVA with Bonferroni post-test). (h) Cell proliferation of mock and SIRT2OE from H7 hESCs and two independent iPSC lines (hiPSC-1 and hiPSC-2) with or without Dox were analyzed by determining cell numbers every 2 days under ESC culture conditions. (mean ± s.d., n=3 biologically independent experiments, * p<0.01; ** p<0.001, two-way ANOVA with Bonferroni post-test). Statistics source data are in Supplementary Table 9.
Supplementary Figure 7 SIRT2 influences metabolic signatures of early differentiation potential of hiPSCs. (a-c) Inducible SIRT2OE hiPSC-1 cells with or without Dox were induced to differentiate spontaneously by culturing in serum-free ITSFn medium for up to 4 days, and gene expression levels of pluripotency markers (Oct4, Nanog, and Rex1) (a), early-differentiation markers (Pax6, Brachyury (B-T), and Sox17) (b) and SIRT2 (c) were determined by qRT-PCR. (mean ± s.d., n=3 biologically independent experiments, * p<0.05, ** p<0.01, one-way ANOVA with Bonferroni post-test). (d) Glycolytic bioenergetics of mock and SIRT2OE hiPSC-1 cells with or without Dox were assessed using the Seahorse XF analyzer. (mean ± s.d., n=3 biologically independent experiments, * p<0.05, ** p<0.01, one-way ANOVA with Bonferroni post-test). (e) Extracellular lactate production of mock and SIRT2OE hiPSC-1 cells with or without Dox. (mean ± s.d., n=3 biologically independent experiments, * p<0.05; ** p<0.01, one-way ANOVA with Bonferroni post-test). (f) Heatmaps depicting gene expression levels of markers representing ectoderm (Pax6, Map2, GFAP and AADC), endoderm (Foxa2, Sox17, AFP, CK8 and CK18), and mesoderm (Msx1 and B-T) in wild type (Mock) and inducible SIRT2OE hiPSC lines including hiPSC-1 and hiPSC-2 with or without Dox for up to 12 days under differentiation conditions. (n=2 biologically independent experiments). 1: Mock w/o Dox, 2: Mock with Dox, 3: SIRT2OE w/o Dox, 4: SIRT2OE with Dox. Statistics source data are in Supplementary Table 9.
Supplementary Figure 8 Effects of altered SIRT1 expression on metabolic reprogramming and iPSC generation. (a) Plasmid map of doxycycline (Dox) inducible SIRT1-EGFP overexpression vector. (b) OCR for hDFs infected with wild type (Mock) or inducible SIRT1-GFP (SIRT1OE) with or without Dox at day 3 post transfection. (mean ± s.d., n=3 biologically independent experiments). (c,d) OCR/ECAR ratio (c), and relative OCR changes after FCCP injection (d) from Mock and SIRT1OE with or without Dox are shown in (b). (mean ± s.d., n=3 biologically independent experiments). (e,f) Effects of SIRT1KD or OE on iPSC generation. Upper: Efficiency of SIRT1KD or OE was confirmed by western blotting with anti-SIRT1 antibody. Lower: Representative pictures of AP-positive colonies at day 14 post-transduction. (mean ± s.e.m., n=3 biologically independent experiments, *** p<0.005, two-tailed unpaired Student’s t-test). (g,h) OCR in hDF infected with Y4 and/or SIRT1OE at 3 (g) or 6 (h) days after transfection. (mean ± s.d., n=3 biologically independent experiments). Statistics source data are in Supplementary Table 9. Unprocessed original scans of blots (e,f) are shown in Supplementary Fig. 9.
Supplementary Figure 9 Unprocessed original scans of Western blots. For some experiments (Figs. 1a,d,i, 2b,c,e,f, 3a, 8b,e, and Supplementary Fig. 1d,g), the independent repeats marked No. 2 and 3 are included. In case of Aldolase A (see input from Fig. 2b,c,e,f), additional non-specific bands were observed probably due to the use of different antibody lot numbers.
Supplementary Figure 9 Continued
**Fig. 2b**

Supplementary Figure 9 continued

**[AcK IB from Aldolase A IP]**

|       | Mock | SIRT2OE |
|-------|------|---------|
|       | - +  | - +     |
| Dox   | - +  | - +     |

**[AcK IB from PGK1 IP]**

|       | Mock | SIRT2OE |
|-------|------|---------|
|       | - +  | - +     |
| Dox   | - +  | - +     |

**[AcK IB from Enolase IP]**

|       | Mock | SIRT2OE |
|-------|------|---------|
|       | - +  | - +     |
| Dox   | - +  | - +     |

**[AcK IB from GAPDH IP]**

|       | Mock | SIRT2OE |
|-------|------|---------|
|       | - +  | - +     |
| Dox   | - +  | - +     |
**Fig. 2b**

Supplementary Figure 9 Continued
Supplementary Figure 9 Continued

Fig. 2c

[Aldolase A IB from AcK IP]

[PGK1 IB from AcK IP]

[Enolase IB from AcK IP]

[GAPDH IB from AcK IP]
Fig. 2c

Supplementary Figure 9 Continued
Supplementary Figure 9 Continued

Fig. 2e

[AcK IB from Aldolase A IP]

[AcK IB from Enolase IP]

[SIRT2 IB from Aldolase A IP]

[SIRT2 IB from Enolase IP]
Supplementary Figure 9 Continued
Supplementary Figure 9 Continued
Supplementary Figure 9 Continued

Fig. 2f

Supplementary Figure 9 continued

Aldolase A (Input)

PGK1 (Input)

Enolase (Input)

GAPDH (Input)

SIRT2 (Input)

β-actin (Input)

hDF Mock SIRT2KD

#1

#2

#3
Supplementary Figure 9 Continued
Supplementary Table Legends

Supplementary Table 1 List of hyperacetylated proteins in hESCs includes five glycolytic enzymes

Supplementary Table 2 List of hypoacetylated proteins in hESCs

Supplementary Table 3 Meta-analyses of hPSCs and their differentiated cells. (a) hESCs, hiPSCs, and their differentiated cells were grouped and meta-

Supplementary Table 4 Meta-analyses of HDAC family gene expression. (a) hESCs, hiPSCs, and their differentiated cells were grouped and meta-

Supplementary Table 5 (a) List of hESC lines and normal somatic cell lines used for web-based data analyses of Fig. 1b and Supplementary Fig. 3c-g. (b)

Supplementary Table 6 Summary of peptide fragments from acetylated lysine residues identified from control and SIRT2KD 293T cells. Symbol @ indicated

Supplementary Table 7 List of the predicted MREs on the SIRT2 mRNAs

Supplementary Table 8 Sequences of primer used for qRT-PCR analyses and cloning

Supplementary Table 9 Statistics source data

References
52. Staege, M.S. et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 64, 8213-8221 (2004).
53. Viemann, D. et al. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. J Leukoc Biol 80, 174-185 (2006).
54. Barbieri, C.E. et al. Mutant human embryonic stem cells reveal neurite and synapse formation defects in type 1 myotonic dystrophy. Cell Stem Cell 8, 434-444 (2011).
55. Sa, S.M. et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178, 2229-2240 (2007).
56. Lu, S.J. et al. GeneChip analysis of human embryonic stem cell differentiation into hemangioblasts: an in silico dissection of mixed phenotypes. Genome Biol 8, R240 (2007).
57. Li, S.S. et al. Target identification of microRNAs expressed highly in human embryonic stem cells. J Cell Biochem 106, 1020-1030 (2009).
58. Duarte, T.L., Cooke, M.S. & Jones, G.D. Gene expression profiling reveals new protective roles for vitamin C in human skin cells. Free Radic Biol Med 46, 78-87 (2009).
59. Maherali, N. et al. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 3, 340-345 (2008).
60. Aasen, T. et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 26, 1276-1284 (2008).
61. Soldner, F. et al. Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964-977 (2009).
62. Yu, J. et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 324, 797-801 (2009).
63. Cheung, H.H. et al. Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br J Cancer 102, 419-427 (2010).
64. Chin, M.H. et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5, 111-123 (2009).
65. Sobrino, A. et al. Estradiol stimulates vasodilatory and metabolic pathways in cultured human endothelial cells. PLoS One 4, e8242 (2009).
66. Marchetto, M.C. et al. Transcriptional signature and memory retention of human-induced pluripotent stem cells. PLoS One 4, e7076 (2009).
67. Jia, F. et al. A nonviral minicircle vector for deriving human iPS cells. Cell Stem Cell 5, 111-123 (2009).
68. Park, H. et al. A nonviral minicircle vector for deriving human iPS cells. Cell Stem Cell 5, 111-123 (2009).
69. Pluchino, S. et al. A nonviral minicircle vector for deriving human iPS cells. Cell Stem Cell 5, 111-123 (2009).
70. Ilipian, M. et al. Trophoblast invasion: assessment of cellular models using gene expression signatures. Placenta 31, 989-996 (2010).
71. Hanna, J. et al. Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc Natl Acad Sci U S A 107, 9222-9227 (2010).
72. Loh, Y.H. et al. Reprogramming of T cells from human peripheral blood. Cell Stem Cell 7, 15-19 (2010).
73. Rose, A.E. et al. Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res 71, 2561-2571 (2011).